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ABSTRACT   There are many environmental, occupational and medical substances that 
cause dysregulation of autoimmunity. Among these substances, the effects and causative 
mechanisms of silica particles and asbestos fibers are discussed in this review. Many 
epidemiological studies have shown a significant association between silica exposure and the 
occurrence of autoimmune diseases such as rheumatoid arthritis (RA), systemic sclerosis (SSc), 
systemic lupus erythematosus (SLE), and anti-neutrophil cytoplasm antibody (ANCA)-related 
vasculitis. Although the importance of NALP3 inflammasome as the initial immune reaction 
against silica particles has been recognized, the processes that form the various autoimmune 
diseases in silica-exposed patients remain unclear. Silica can activate various immune cells 
and cause an unbalance of regulatory T cells, responder T cells and T helper 17 cells, which 
might be key factors in understanding the silica-induced autoimmune alteration. In contrast, 
asbestos exposure shows a smaller association with autoimmune diseases. However, interesting 
findings have been reported regarding anti-endothelial and mesothelial cell antibodies detected 
in asbestos-exposed patients. Further investigations may contribute to elucidation of the 
mechanisms involved in environmental factor-induced modification of autoimmunity.
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〈Review〉
INTRODUCTION
   It is well known that various environmental factors 
such as chemical agents, including silica, asbestos, 
metals, pesticides and solvents, physical agents such 
as ionizing radiation, ultraviolet radiation (sunlight), 
electric and magnetic fields, and biological agents 
that include infectious microorganisms, foods, 
molds, mycotoxins, and other toxins may influence 
the human immune system, particularly in regard 
to dysregulation of autoimmuni ty１－７）. Many 
epidemiological investigations and experimental 
studies have evaluated environmental factors 
that induce autoimmune diseases１－７）. In order to 
investigate the biological mechanisms by which 
these environmental factors cause autoimmune 
diseases, it is important to conduct risk and hazard 
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analyses of environmental and occupational 
substances, as well as safeguard the health of 
workers in various occupational situations and 
people living in hazardous residential areas１－７）. In 
addition to these aims, these investigations may be 
useful in determining the causative mechanisms 
of various autoimmune diseases, among which the 
pathophysiological and immunological aspects are 
well known, but the causative mechanisms remain 
unclear８－10）. 
   In this review, we investigate silica and mineral 
silicate, a form of asbestos, by evaluating and 
discussing epidemiological and experimental 
findings  in  an  effor t  to  be t te r  unders tand 
environmental  factor- induced autoimmune 
disorders.
SILICA
Epidemiological studies
   There  a re  many  repor t s  desc r ib ing  the 
epidemiological significance of silica exposure 
and complicated autoimmune diseases. Caplan 
syndrome, complicated pneumoconiosis, and 
rheumatoid arthritis (RA) were initially reported 
in 1953 by Caplan11）. Although it was thought that 
the causes of pneumoconiosis were not confined to 
silica, and included coal and asbestos, subsequent 
reports suggested that silica is the most common 
cause of this syndrome12－17）. Another important 
syndrome involves complications of silicosis 
and systemic sclerosis, and is known as Erasmus 
syndrome. In 1957 Erasmus described an apparently 
high prevalence of progressive systemic sclerosis 
(PSS) / systemic sclerosis (SSc) in Witwatersrand 
gold miners exposed to dust containing free silica18）. 
   Recent epidemiological investigations involving 
meta-analysis of factors associated with exposure 
to silica indicate that the relative risk for RA in 
the silica-exposed population is more than three 
times higher than that of non-exposed people19－22）. 
Meta-analysis has also been used to investigate the 
association between silica and SSc22－23）. All of these 
studies indicate the significant high risk of SSc in 
the silica-exposed population22－23）. Studies have also 
been performed regarding the association between 
silica exposure and systemic lupus erythematosus 
(SLE)22，24－28）. A positive association was reported in 
each of these studies and a high risk was indicated. 
In addition, case reports and case-control studies 
have been conducted concerning complications 
of anti-neutrophil cytoplasmic antibody (ANCA)-
related vasculitis 29－40）.  These investigations 
revealed a higher prevalence of ANCA in silicosis 
patients 29－40）.
   The overall findings of these epidemiological 
studies indicate with certainty that silica exposure 
alters human autoimmune tolerance and causes 
various autoimmune diseases.
Mechanistic investigations 
   Investigations concerning the mechanisms by 
which silica exposure affects the regulation of 
autoimmunity suggest that inflammasomes are 
very important41－45）. They contribute toward the 
innate immunity against various external factors 
(including silica, asbestos, bacteria and their toxins) 
and internal factors (including crystalline derived 
from uric acid and cholesterol) that represent 
danger signals which need to be handled as the 
first step in a series of successive phenomena. The 
inflammasomes are large multi-molecular complexes 
composed of caspase-1, PYCARD/ASC (apoptosis-
associated speck-like protein containing caspase 
recruitment domain), and NALPs (a type of NOD-
like receptors) that induce the secretion of mature 
interleukin (IL)-1β and IL-18 (pro-inflammatory 
cytokines) from antigen-presenting cells (APC)46
－50）. Although the activation of inflammasomes 
can contribute to the formation of lung fibrosis 
in silicosis and asbestosis, two typical forms of 
pneumoconiosis51－53）, the long-term and gradual 
development of dysregulation of autoimmunity 
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may require additional cellular and molecular 
mechanisms involving various cell-to-cell, cytokine-
to-cytokine, and molecule-to-molecule interactions. 
   There are many players in the development of 
autoimmune diseases when considering cell-to-cell 
interactions, such as APCs to present self-antigens, 
T cells to recognize them, B cells to produce 
antibodies, regulatory T cells (Treg) to control / 
inhibit the self-reactivity, and T helper (Th) 17 cells 
to promote hyper-reactivity to self-antigens54－58）. 
The cytokine network plays a key role during any 
alteration or disturbance of the control of immune 
tolerance59－63）. As mentioned above, IL-1β and 
IL-18 are produced from APC46－50）. IL-1α is also 
secreted from monocyte-macrophage-APC cells 
and has various biological effects on immune, 
neurological and hematological conditions. IL-1α 
can expand Th1 cells to produce interferon (IFN)-
γ. IFN-γ stimulates genes such as interferon 
regulatory factor 1 (IRF1) as the transcription factor 
to activate immune reactions64，65）. The networks 
then enlist nuclear factor-κB (NFκB) to activate 
self-antigen reacting immune cells such as B cells 
and T cells.
   Unfortunately, it is not fully understood how the 
silica particles activate these networks through cell, 
cytokine and molecular interactions. The activation 
of inflammasomes is only the initial step of a series 
of cascading events that induce dysregulation of 
autoimmunity46－50）.
Silica-induced chronic activation of T cells
   In addition to the adjuvant effects of silica 
that present various self-antigens to APCs with 
sufficient size as antigens, silica particles can 
also activate responder Th1 cells and Treg as we 
reported previously66－70）. Evidence of silica-induced 
activation was found with the expression of CD69, 
an early activation T-cell marker, when T cells were 
cultured with silica particles in vitro and resulted 
in a remarkably higher expression of Programed 
Death-1 (PD-1) genes in peripheral blood T cells 
compared to those derived from healthy donors 
(HD), as well as higher soluble IL-2 receptor (R) in 
the serum of silicosis patients compared to HD66－70）.
   Silica also changes activation-induced cell death 
in stimulated helper T cells by altering transcription 
of the Fas/CD95 cell death receptor gene, and 
results in the longer survival of these T cells71－75）. 
Soluble Fas (sFas), an alternative spliced variant of 
the Fas gene, was more highly expressed relative 
to the wild-type Fas transcript in T cells from 
silicosis patients compared to those from HD72－74）. 
In addition, sFas was elevated in the serum of 
silicosis patients75）. sFas prevents activation-induced 
cell death in stimulated T cells, resulting in the 
long-term survival of these T cells in which self-
recognizing clones may be present72，76－79）. 
   In contrast to results obtained for responder T 
cells, Treg expressed Fas/CD95 to a much higher 
level when it was chronically activated, and Fas/
CD95 expression was higher in Treg derived 
from the peripheral blood of silicosis patients 
compared to HD70）. Furthermore, peripheral blood 
mononuclear cells from HD were cultured with 
silica particles and results indicated that forkhead 
box P3 (FoxP3) gene positive Treg was decreased70）. 
The overall findings indicate an unbalance, increase 
of responder T cells, and decrease of Treg that may 
form the base condition in silicosis patients for the 
development of dysregulation of autoimmunity76－79）.
Th17 and silicosis
   A consideration of autoimmune diseases indicates 
that another T-cell type, Th17, plays an important 
role. The balance between Treg and Th17 is critical 
for the development of autoimmune diseases; Treg 
can be induced by transforming growth factor (TGF) 
β and IL-2, and if IL-6 is also present, T cells are 
polarized to Th17 rather than Treg. The decrease 
of Treg and increase of Th17 may be the important 
factors that induce autoimmune diseases80－85）.
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   However, the relationship between silica exposure 
and alteration of Th17 cells remains unclear. It has 
been reported that Th17 can regulate silica-induced 
lung inflammation through an IL-1β-dependent 
mechanism80－85）. As mentioned above, pulmonary 
inflammation and development of fibrosis in the 
lung may initially be induced by activation of the 
NALP3 inflammasome, and the previous findings 
therefore seem reasonable. This would ensure 
direct and recurrent contact between Th17 cells and 
inhaled remaining silica particles in the lung, as 
well as in lymph nodes, and may alter the features 
of Th17 cells. Additionally, chronic inflammation 
and progression of lung fibrosis may alter cytokine 
conditions toward an IL-6-dominant state in silicosis 
patients to result in a Th17-dominant and Treg-
reduced situation in these patients80－85）. Factor-
analysis of our preliminary data indicated that the 
serum IL-6 level is included in the same factor 
with the titer of anti-nuclear antibody (ANA) and 
serum level of ANCA when the levels of various 
cytokines and titers of auto-antigens were analyzed 
in silicosis patients. This may suggest that the level 
of IL-6 (as well as TGF-β) is a key factor for the 
detection of silicosis patients prone to dysregulation 
of autoimmunity80－85）.
MINERAL SILICATE, ASBESTOS
   We would like to turn our attention now to the 
mineral silicate, a form of asbestos. The core 
molecule of asbestos comprises Si and O, and is 
therefore similar to silica. The physical features 
of asbestos differ completely from those of 
silica, and partly result from the fact that silica 
comprises particulate matter, whereas asbestos 
is fibrous and includes various other minerals 
such as magnesium and iron. Silica and asbestos 
exposure causes pneumoconiosis,  i .e. ,  lung 
fibrosis, and both are categorized as a Group 1 
carcinogen by the International Agency for Cancer 
Research (IARC)86，87）. However, evidence that 
asbestos causes dysregulation of autoimmunity 
is insufficient, and contrasts with the affirmative 
evidence found for silica88－95）. Several case-control 
studies have shown a positive concern for the role of 
asbestos exposure in the development of RA88－95）. 
Furthermore, some studies have shown immune 
enhancement or activation of autoimmunity defined 
by elevated immunoglobulins, rheumatoid factors, 
and ANA or ANCA following asbestos exposure 
without any confirmed symptoms of autoimmune 
diseases88－95）. 
   Some interesting investigations have been 
published regarding the impact of asbestos 
exposure96－100）. These reports indicated that asbestos 
exposure induces production of autoantibodies 
against specific cell types, and complement previous 
reports showing the presence of anti-endothelial cell 
antibodies in vasculitis, SSc and SLE101－103）. Similar 
to findings concerning these antibodies, reports 
indicate that anti-fibroblast antibodies (AFAs) 
and anti-mesothelial cell antibodies (MCAAs) are 
present respectively in the serum of mice and humans 
that have been exposed to “Libby Amphibole 
(LA)”96－100）. LA is a mixture of amphibole fibers 
that contaminated the vermiculite that was mined 
outside of Libby, Montana, U.S.A. The interesting 
aspects of these antibodies include collagen 
production caused by binding with target cells such 
as AFAs to fibroblasts, and MCAAs to mesothelial 
cells96－100）. The overall results suggest that asbestos 
exposure and production of these antibodies may 
play causative roles in asbestos-induced fibrosis 
formation in the lungs and pleura96－100）. 
   Although these findings were not consistent with 
systemic autoimmune diseases, it is very interesting 
that antibodies against these specific cell types may 
contribute to asbestos-induced disease formation 
such as fibrosis96－100）.
CONCLUSION
   There are many reviews of environmental 
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substances, drugs and chemicals that cause 
dysregulation of autoimmunity1－7）. Various drugs 
including hydralazine, quinidine and procainamide 
are associated with the development of SLE1－7）. 
Silica and silicone (breast augmentation) are known 
to be related to SSc1－7）. In addition, certain 
organic chemicals such as aromatic hydrocarbons, 
including toluene, benzene and xylene, aliphatic 
chlorinated hydrocarbons such as vinyl chloride, 
trichloroethylene and perchloroethylene, epoxy 
resins, and metaphenylenediamine are known to 
cause SSc following environmental or occupational 
exposure1－7）. 
   In this review, we only focused on silica and 
silicate, a form of asbestos, since silica is known 
as the most frequent environmental factor causing 
dysregulation of autoimmunity1－7）. The summarized 
findings detailed in this review are presented in Fig. 
1. New cases of pneumoconiosis, including silicosis 
and asbestosis, have been rapidly decreasing 
in the previous two to three decades because 
of improvement in occupational environments 
Fig. 1.　Schematic presentation of the biological effects of silica and mineral silicate, a form of asbestos, detailing fibrous 
changes in the lung, autoimmune diseases in silica-exposed patients, cancer in asbestos-exposed patients, immune stimulation and 
activation to yield various auto-antibodies, complications of autoimmune diseases in silica-exposed patients, and production of 
antibodies against endothelial and mesothelial cells in asbestos-exposed patients through activation of inflammasomes.
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and material handling procedures. However, 
we now have to consider low-level exposure to 
environmental factors causing autoimmune diseases, 
as well as individual factors such as HLA types and 
single nucleotide polymorphism (SNP) in certain 
genes, including the epigenetic status of various 
genes, since these situations may influence the 
occurrence of systemic autoimmune diseases due to 
the relationship between exposure to environmental 
factors and individual situations.
   Further studies are required to elucidate the 
detailed pathogenic mechanisms involved in 
environmental factor-induced dysregulation of 
autoimmunity. These investigations may contribute 
to the development of tools for the prevention and 
treatment of various autoimmune disorders.
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